Sara J. Buhrlage, Ph.D.
Affiliations: | 2015 | Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA, United States |
Area:
Chemical biologyGoogle:
"Sara Buhrlage"Mean distance: 8.57 | S | N | B | C | P |
Parents
Sign in to add mentor| Anna K. Mapp | grad student | 2008 | University of Michigan | |
| (Small molecule transcriptional activation domains.) | ||||
| Nathanael Gray | research scientist | 2010-2015 | Harvard Medical School/Dana-Farber Cancer Institute | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Koduri V, Duplaquet L, Lampson BL, et al. (2021) Targeting oncoproteins with a positive selection assay for protein degraders. Science Advances. 7 |
| Donovan KA, Ferguson FM, Bushman JW, et al. (2020) Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell |
| Weisberg E, Parent A, Yang PL, et al. (2020) Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharmaceutical Research. 37: 167 |
| Schauer NJ, Liu X, Magin RS, et al. (2020) Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Scientific Reports. 10: 5324 |
| Weisberg E, Meng C, Case A, et al. (2020) Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia |
| Yang J, Meng C, Weisberg E, et al. (2020) Inhibition of the deubiquitinase USP10 induces degradation of SYK. British Journal of Cancer |
| Munshi M, Liu X, Chen JG, et al. (2020) SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer Journal. 10: 12 |
| Weisberg E, Meng C, Case AE, et al. (2020) Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. Journal of Cellular and Molecular Medicine |
| Weisberg E, Meng C, Case AE, et al. (2019) Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British Journal of Haematology |
| Wang L, Ferrao R, Li Q, et al. (2019) Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4). The Journal of Biological Chemistry |